EcoDrugPlus

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSPPYG00000041378
Gene Symbol: PSENEN
5 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Progesterone Receptor

Ensembl ID : ENSPPYG00000003801
Gene Symbol: PGR
5 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin D2 Receptor

Ensembl ID : ENSPPYG00000005816
Gene Symbol: PTGDR
4 Cross references
118 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin D2 Receptor 2

Ensembl ID : ENSPPYG00000003204
Gene Symbol: PTGDR2
5 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 1

Ensembl ID : ENSPPYG00000009644
Gene Symbol: PTGER1
5 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 2

Ensembl ID : ENSPPYG00000005817
Gene Symbol: PTGER2
5 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 3

Ensembl ID : ENSPPYG00000001241
Gene Symbol: PTGER3
5 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 4

Ensembl ID : ENSPPYG00000015419
Gene Symbol: PTGER4
5 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin I2 Receptor

Ensembl ID : ENSPPYG00000010155
Gene Symbol: PTGIR
5 Cross references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSPPYG00000019571
Gene Symbol: PTGS1
5 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSPPYG00000000408
Gene Symbol: PTGS2
5 Cross references
237 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSPPYG00000030380
Gene Symbol: PSMA2
5 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).